Thomas J. Schnitzer mainly investigates Osteoarthritis, Internal medicine, Placebo, Surgery and Anesthesia. His Osteoarthritis research is multidisciplinary, relying on both Gait, Physical therapy and Knee Joint. The study incorporates disciplines such as Gastroenterology, Perforation and Ibuprofen in addition to Internal medicine.
His work in Gastroenterology tackles topics such as Upper gastrointestinal bleeding which are related to areas like Etoricoxib. His Placebo research incorporates elements of Adverse effect, Clinical trial, Chemotherapy and WOMAC. His research in Surgery intersects with topics in Urology, Rheumatoid arthritis, Osteoporosis, Naproxen and Bone remodeling.
His main research concerns Osteoarthritis, Internal medicine, Placebo, Physical therapy and Surgery. Thomas J. Schnitzer interconnects Celecoxib, Visual analogue scale, Anesthesia and Adverse effect in the investigation of issues within Osteoarthritis. His Internal medicine research includes themes of Gastroenterology, Endocrinology and Naproxen.
His Placebo research incorporates themes from Clinical trial, Tolerability, Randomized controlled trial, Chronic pain and WOMAC. In his research, Back pain is intimately related to Neuroimaging, which falls under the overarching field of Chronic pain. In his work, Osteoporosis, Bone remodeling and Femoral neck is strongly intertwined with Urology, which is a subfield of Surgery.
Thomas J. Schnitzer spends much of his time researching Osteoarthritis, Placebo, Internal medicine, Chronic pain and Tanezumab. His Osteoarthritis research is multidisciplinary, incorporating elements of Nociception, Analgesic, Tolerability, Arthroplasty and Physical therapy. His Analgesic research includes themes of Gastroenterology, Synovitis and Neutropenia.
The concepts of his Placebo study are interwoven with issues in Clinical trial, Adverse effect, Mixed anxiety-depressive disorder, Duloxetine and WOMAC. His research investigates the connection between Chronic pain and topics such as Back pain that intersect with problems in Physical medicine and rehabilitation, Socioeconomic status, Clinical psychology and Naproxen. His study in Tanezumab is interdisciplinary in nature, drawing from both Anesthesia, Joint pain, Randomization and Low back pain.
Thomas J. Schnitzer mostly deals with Placebo, Internal medicine, Osteoarthritis, Chronic pain and WOMAC. His work carried out in the field of Placebo brings together such families of science as Clinical trial, Cortical bone, Bone resorption, Teriparatide and Bone remodeling. His Internal medicine research incorporates elements of Orthopedic surgery and Distal femur.
He combines subjects such as Analgesic and Tolerability with his study of Osteoarthritis. His work deals with themes such as Biomarker, Back pain and Functional magnetic resonance imaging, which intersect with Chronic pain. His research investigates the connection with WOMAC and areas like Randomized controlled trial which intersect with concerns in Dentistry, Bone density and Bone adaptation.
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier;Loren Laine;Alise Reicin;Deborah Shapiro.
The New England Journal of Medicine (2000)
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update
R. D. Altman;M. C. Hochberg;R. W. Moskowitz;T. J. Schnitzer.
Arthritis & Rheumatism (2000)
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Daniel O. Clegg;Domenic J. Reda;Crystal L. Harris;Marguerite A. Klein.
The New England Journal of Medicine (2006)
Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology.
M C Hochberg;R D Altman;K D Brandt;B M Clark.
Arthritis & Rheumatism (1995)
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Deepak L. Bhatt;Deepak L. Bhatt;Byron L. Cryer;Charles F. Contant;Marc Cohen.
The New England Journal of Medicine (2010)
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Kenneth G. Saag;Ronald Emkey;Thomas J. Schnitzer;Jacques P. Brown.
The New England Journal of Medicine (1998)
Guidelines for the medical management of osteoarthritis
Marc C. Hochberg;Roy D. Altman;Kenneth D. Brandt;Bruce M. Clark.
Arthritis & Rheumatism (1995)
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials
Colin Baigent;N. Bhala;J. Emberson;A. Merhi.
The Lancet (2013)
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Thomas J Schnitzer;Gerd R Burmester;Eduardo Mysler;Marc C Hochberg.
The Lancet (2004)
Corticostriatal functional connectivity predicts transition to chronic back pain.
Marwan N Baliki;Bogdan Petre;Souraya Torbey;Kristina M Herrmann.
Nature Neuroscience (2012)
If you think any of the details on this page are incorrect, let us know.